Phibro Animal Health Corporation (NASDAQ:PAHC – Get Free Report) has received an average rating of “Hold” from the five research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $42.50.
Several equities analysts have recently commented on the company. Wall Street Zen cut Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings cut shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Citigroup reduced their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Finally, Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st.
View Our Latest Research Report on PAHC
Phibro Animal Health Stock Up 3.6%
Phibro Animal Health (NASDAQ:PAHC – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The business had revenue of $383.54 million for the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, equities analysts forecast that Phibro Animal Health will post 3.08 EPS for the current fiscal year.
Phibro Animal Health Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd were paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date was Wednesday, June 3rd. Phibro Animal Health’s dividend payout ratio is 20.60%.
Insider Activity at Phibro Animal Health
In related news, CEO Jack Bendheim sold 7,040 shares of Phibro Animal Health stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $55.80, for a total value of $392,832.00. Following the completion of the transaction, the chief executive officer directly owned 67,720 shares in the company, valued at approximately $3,778,776. This trade represents a 9.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 18,608 shares of company stock worth $983,825 over the last quarter. Company insiders own 50.13% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. 1620 Investment Advisors Inc. increased its holdings in shares of Phibro Animal Health by 77.4% in the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after acquiring an additional 295 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after purchasing an additional 386 shares during the period. KBC Group NV acquired a new position in Phibro Animal Health in the first quarter worth $29,000. Rothschild Investment LLC increased its stake in Phibro Animal Health by 2,500.0% during the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after purchasing an additional 1,000 shares during the last quarter. Finally, iSAM Funds UK Ltd bought a new stake in Phibro Animal Health during the third quarter valued at $61,000. Institutional investors and hedge funds own 99.34% of the company’s stock.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
Featured Stories
- Five stocks we like better than Phibro Animal Health
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
